Partnering with EpiVax
EpiVax is a premier partner for biotech and pharmaceutical companies, with over 25 years of experience in the field of immunology. We offer strategic partnership agreements to extend our advanced capabilities, including deimmunization, humanization, and tolerization of protein therapeutics, as well as the design and optimization of vaccines for both humans and swine.
Our expertise in immune modulation and rapid vaccine design positions us as leaders in computational immunology and vaccinology. Our innovative tools have been instrumental in developing highly immunogenic vaccines and selecting the best strains of circulating viruses for vaccine production. EpiVax’s proven methods have been extensively validated, and our many successful collaborations have consistently resulted in safer and more effective therapies.
Publication: Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy. Expert Review of Vaccines. 2022.
Ancer®: A Personalized Cancer Vaccine Design Toolkit
Neoantigen-driven, personalized cancer vaccines (NEO-PCVs) represent the future of cancer treatment. These vaccines harness the power of next-generation sequencing (NGS) to identify unique tumor mutations, known as neoantigens, which are the primary targets of effective immune responses. By boosting the immune system’s response to these specific mutations, NEO-PCVs offer a tailored approach to cancer therapy. This precision immunotherapy promises to transform oncology, providing nearly every cancer patient with a powerful new weapon against their disease.
Ancer® is an end-to-end, automated neoantigen identification and personalized cancer vaccine design platform available for licensing. Integrating multiple advanced algorithms into a single pipeline to rapidly design custom therapies for individual cancer patients, it uses each patient’s own tumor genome sequence as the starting point.
Superior Vaccine Design and Development
EpiVax partners with pharmaceutical, biotech, and academic organizations to design and develop innovative vaccines. With over 25 years of experience, our team excels in identifying T cell epitopes that trigger strong immune responses, enabling precise epitope mapping, antigen selection, immunogen design, and prediction of vaccine efficacy.
We specialize in selecting immunogenic epitopes, re-engineering antigens for enhanced immunogenicity, and eliminating unwanted regulatory T cell epitopes. This ensures our designed antigens provide superior protection against diseases, crucial for rapid and effective vaccine responses to emerging infectious diseases and biothreats.
Partnering with EpiVax grants you access to our expert-driven analyses and tailored insights, accelerating the development of safer, more effective vaccines for humans and livestock, advancing global health outcomes.
Press: EpiVax Joins Intravacc, CEPI on Project to Develop Universal Betacoronavirus Vaccine.
Tregitopes™: Tolerance-Inducing Peptides
Tregitopes™, discovered by EpiVax, are immune-modulating peptides derived from human immunoglobulin. These linear sequences activate natural regulatory T cells and exhibit characteristics such as binding to multiple MHC class II molecules, suppressing effector T-cell responses, and up-regulating Treg-associated cytokines and chemokines in various disease models.
Extensively validated both internally and externally, this natural approach to immune modulation could provide a safer alternative to traditional immunosuppressive drugs. Licensing Tregitopes™ from EpiVax offers therapeutic developers a strategic edge in the evolving landscape of immune therapies.
Potential applications for Tregitopes™:
- Autoimmune and inflammatory conditions
Eg.: Type 1 Diabetes, Crohn’s disease, Rheumatoid Arthritis, and inflammatory bowel disease
- Allergy treatments
Eg.: Food allergy, asthma
- Tolerance induction to biologics, protein therapeutics, transplants, etc.
Publication: Tregitopes improve asthma by promoting highly suppressive and antigen-specific Tregs. Frontiers in Immunology. 2021.